Sermorelin + MOTS-c Stack: When to Pick One Over Both

The direct answer

There is no evidence-based reason to choose the combination. MOTS-c has never been given to a human in a published study, so a sermorelin-plus-MOTS-c pairing has no human outcome, dose or safety data behind it [2]. Sermorelin has limited human data: growth in children with a diagnosed deficiency, and 14 days of hormone levels in older men [4][5].

MOTS-c's metabolic effects come from mice and cells, with no human dose, no human safety data and no measured human pharmacokinetics [2].

What sermorelin is, and what the human data actually show

Sermorelin is a 29-amino-acid analogue of human growth hormone-releasing hormone and the shortest synthetic peptide with the full biological activity of GHRH [1]. It is not growth hormone. It acts on the pituitary's GHRH receptor to make the body release its own growth hormone; after an intravenous dose in healthy men the peptide was eliminated quickly, yet growth hormone levels stayed raised for about 3 hours [11].

The approval history matters. Sermorelin acetate was approved as Geref under two applications: a 0.05 mg per ampule diagnostic product (NDA 019863, approved December 28, 1990) and 0.5 mg and 1 mg vials for idiopathic growth hormone deficiency in children with growth failure (NDA 020443, approved September 26, 1997) [6]. The manufacturer discontinued both in 2008 and FDA withdrew the approvals effective June 18, 2009 [6]. In March 2013 FDA determined that Geref was not withdrawn for reasons of safety or effectiveness [6]. The approved uses were the pediatric treatment and a pituitary diagnostic test only — not adults, anti-aging, weight loss or athletic performance [6].

The pediatric trial. An open-label, multicenter, 1-year study enrolled 110 previously untreated prepubertal children with growth hormone deficiency; 86 were evaluable. The dose in the study was 30 micrograms per kg subcutaneously at bedtime. Mean height velocity rose from 4.1 cm/yr at baseline to 8.0 cm/yr at 6 months and 7.2 cm/yr at 12 months, and 74% were considered good responders at 6 months. No adverse changes appeared in general biochemistry or hormone tests, fasting glucose did not change, IGF-I was not excessively raised, and the peptide was well tolerated overall [4].

The older-men study. Ten healthy men with a mean age of 68 took 0.5 mg and 1 mg of GHRH(1-29) subcutaneously twice daily for 14 days each, in random order, and were compared with nine men with a mean age of 26. At the 1 mg dose, 24-hour growth hormone and IGF-I rose to levels not significantly different from the young men [5]. This was a short physiology study. It measured hormone levels, not body composition, strength or any clinical outcome [5].

What MOTS-c is, and where the evidence stops

MOTS-c stands for mitochondrial open reading frame of the 12S rRNA-c: a 16-amino-acid peptide with a molecular weight of about 2174.6 g/mol, encoded in mitochondrial DNA, first reported in 2015 by Lee and colleagues in Cell Metabolism [2][3].

In mice, MOTS-c treatment prevented age-dependent and high-fat-diet-induced insulin resistance and diet-induced obesity; skeletal muscle appeared to be the main target organ, and its cellular actions inhibited the folate cycle, leading to AMPK activation [3]. In one mouse study, injected MOTS-c reduced weight gain on a high-fat diet — roughly 20% lower body weight after 8 weeks at 0.5 mg/kg/day intraperitoneal — and a late-life schedule of 15 mg/kg three times weekly from 23.5 months of age lengthened median lifespan from 912 to 970 days [2].

Human work has measured the body's own MOTS-c, not injected peptide. In one study, exercise induced endogenous MOTS-c expression in skeletal muscle and in circulation; the people studied were not given MOTS-c [12]. A randomized trial of 30 healthy adults assigned to endurance exercise (n=10), resistance exercise (n=10) or control (n=10) found circulating MOTS-c showed only a trend to increase after endurance exercise, and plasma MOTS-c was not related to fitness [13].

FDA's July 2026 review searched PubMed, Embase, the Cochrane library and other sources and found no clinical study in which MOTS-c, compounded or not, was given to a human; the 12 papers the nominator cited were not clinical studies [2]. There is no human dosing study — the nominated products were 5 mg and 10 mg subcutaneous injections, and the rodent doses of 0.5 to 15 mg/kg cannot be converted into human doses [2]. FDA found no pharmacokinetic data in humans or live animals; the only kinetic observation is rapid breakdown in human blood in a laboratory dish, which raises the question whether injecting it can produce active levels in people at all [2].

Is there any basis for using both together?

The two peptides are described through different mechanisms. Sermorelin works at the pituitary GHRH receptor [1]. MOTS-c's AMPK effects have been shown in mouse skeletal muscle [3], although FDA says the molecular targets are unknown and no dose-response relationships were assessed [2]. A difference in mechanism does not show that the two together do more than either alone; that would need a comparison study, and no human study of the pair exists.

Adding a peptide with no human exposure data, no animal toxicity studies and no immunogenicity data [2] does not build on sermorelin's human data; it adds a separate unknown.

When sermorelin is the one with evidence behind it

If the question is growth hormone output, sermorelin is the only one of the two with human hormone measurements [4][5]. Its documented use is pediatric growth hormone deficiency, where the pivotal program used 30 micrograms per kg once daily at bedtime [4]. The adult data reach 14 days of twice-daily dosing in ten older men [5]. Geref was never approved for adults [6].

Neither of the two sermorelin studies described here measured body composition or physical performance [4][5].

When MOTS-c comes up on its own

MOTS-c was nominated for insulin resistance, obesity, osteoporosis, vascular calcification, muscle and fat metabolism, and longevity, as 5 mg and 10 mg subcutaneous injections [2]. FDA staff recommended against adding it to the pharmacy bulks list, citing that it is not well characterized (inconsistent naming, no impurity, aggregate or endotoxin data), has unknown use in compounding, no human safety or effectiveness data, no animal toxicity studies, and that FDA-approved treatments exist for obesity and osteoporosis, two of the nominated uses [2].

FDA's safety-risk page adds its stated concerns: the agency has not identified any human exposure data on drug products containing MOTS-c by any route, the substance lacks important safety information, and injectable peptides may pose immunogenicity risk from aggregation and peptide-related impurities. Removal from the highest-risk category was not a finding that it is safe [14].

So the two are not equal options with different targets. One has pediatric and short-term adult human studies; the other has none [4][5][2].

Where each one legally stands

Neither peptide is available as an FDA-approved product today. Sermorelin products in the US are compounded, and compounded drugs are not FDA-approved — FDA does not review their safety, effectiveness or quality before they are marketed [15][6]. Sermorelin acetate sits in category 1 (under evaluation) on FDA's nominated bulk substances list for outsourcing facilities, marked as a substance that is a component of FDA-approved drugs [7]. It does not appear in any category on FDA's list for state-licensed pharmacies and physicians updated May 14, 2026 [8], and it is not one of the six peptides in HHS's October 2026 draft enforcement-discretion policy [16].

MOTS-c is not an FDA-approved drug and is not a component of one; FDA's July 2026 review found no USP or National Formulary monograph, no listing in the European or Japanese pharmacopeias, and no product authorized by the European Medicines Agency [2]. It appears in the 'nominated but withdrawn' table on FDA's page for bulk substances that may present significant safety risks [14], and in none of the three categories on FDA's list for state-licensed pharmacies and physicians or on its list for outsourcing facilities [8][7]. On July 23, 2026 the Pharmacy Compounding Advisory Committee voted in favour of adding it to the bulks list, against FDA staff's recommendation; that advice is not binding, it is not on the list, and adding it takes formal rulemaking [17][15]. HHS's draft policy of October 2026 names MOTS-c among six peptides and says HHS does not intend to take enforcement action against a state-licensed pharmacy, federal facility or licensed physician compounding it (acetate form, subcutaneous or intramuscular injection) if the policy's conditions are met — but the notice states it is not binding, establishes no rights, and is neither an approval nor a listing [15][16].

Both are banned in sport

WADA's Prohibited List names sermorelin in S2.2.4 (growth hormone releasing factors) and MOTS-c in S4.4.1 (metabolic modulators, AMPK activators). Both are prohibited at all times, in and out of competition, and both classes are non-Specified Substances [9]. Both are on the 2026 List and remain on the 2027 List [9][10].

What to watch for

In the 1-year pediatric trial, sermorelin was well tolerated, with no adverse changes in general biochemistry or hormone tests, no change in fasting glucose and no excessive IGF-I rise [4].

For MOTS-c, human safety is unknown. FDA found no clinical studies, no human exposure data by any route and no animal toxicity studies, and no immunogenicity data exist for the 16-amino-acid peptide. The agency's stated concern for an injected product is immunogenicity from aggregation and peptide-related impurities [2]. Its searches of the adverse-event database through March 9, 2025 retrieved no MOTS-c reports [2].